Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy-Reference-Cited by-同舟云学术

Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy

Published:2021-10-15 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Jordie Eric Burroughs¹^ORCID,Gibiansky Leonid²,Knab Timothy¹,Lemenuel‐Diot Annabelle³,Ravva Patanjali⁴,Zwanziger Elke³,Jolivet Sebastien³,Bhardwaj Rajinder⁵,Hernández‐Sánchez Jules⁶,Nasmyth‐Miller Clare⁶,Sturm Stefan³

Affiliation:

1. Translational & Systems Pharmacology Metrum Research Group LLC Tariffville CT USA

2. QuantPharm LLC North Potomac MD USA

3. Roche Innovation Center Basel Roche Pharmaceutical Research and Early Development Basel Switzerland

4. Roche Innovation Center New York Roche Pharmaceutical Research and Early Development New York NY USA

5. Integrated Drug Development Certara Strategic Consulting Parsippany NJ USA

6. Roche Products Limited Product Development Welwyn Garden City UK

Funder

Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15059

Reference33 articles.

1. Neuraminidase Inhibitors for Influenza

2. Tamiflu® US Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021087s068 021246s051lbl.pdf. Accessed February 2 2021.

3. Roche Pharmaceuticals.Tamiflu® (oseltamivir) summary of product characteristics.https://www.ema.europa.eu/en/documents/product-information/tamiflu-epar-product-information_en.pdf. Accessed February 2 2021.

4. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients

5. Recovery of Drug‐Resistant Influenza Virus from Immunocompromised Patients: A Case Series